NewAmsterdam Pharma Co N.V.

Listed Company

NAMSCIK 0001936258NasdaqLarge AcceleratedPharmaceutical PreparationsP7NLFY ends Dec 31

Period

FY 2025

Revenue

$22.50M

Net Income

$-203.82M

Total Assets

$769.28M

Equity

$683.43M

Shares Out

114.98M

Op. Cash Flow

$-147.78M

Business

NewAmsterdam Pharma Co N.V. is a late-stage biopharmaceutical company developing obicetrapib, an oral, low‑dose, highly selective CETP inhibitor to address unmet needs in patients with cardiometabolic disease and elevated LDL‑C. Its main products under development are obicetrapib monotherapy and a fixed‑dose combination with ezetimibe, supported by multiple Phase 2 and Phase 3 trials and related clinical programs. The company’s activities are organized around clinical development and regulatory programs, strategic partnerships and commercialization planning, and outsourced manufacturing and supply. It pursues regulatory approval and market access in the United States, the EU, Japan, China and the United Kingdom, planning U.S. commercialization itself and third‑party commercialization or licensing (e.g., Menarini) in other territories.

Summary from filing dated 2025-02-26

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	23	46	14	103	—
Research and development expenses	142	151	159	87	29
Selling, general and administrative expenses	106	70	38	20	6
Total operating expenses	248	222	197	106	35
Operating loss	−226	−176	−183	−4	−35
Interest income	28	17	11	—	—
Fair value change - earnout	4	−37	−266,000	−707,000	—
Fair value change - warrants	−23	−39	−10	−334,000	—
Foreign exchange gains/(losses)	13	−7	5	−10	2
Loss before tax	−204	−242	−177	−23	−42
Income tax expense (benefit)	—	−1,000	27,000	—	—
Loss for the year	−204	−242	−177	−23	−42
Unrealized gain on available-for-sale securities, net of tax	326,000	45,000	—	—	—
Total comprehensive loss for the year, net of tax	−203	−242	−177	−12	−41
Basic	−1.72	−2.56	−2.15	−1.19	−3.81
Diluted	−1.72	−2.56	−2.15	−1.19	−3.81

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	490	772	340	—	—
Prepayments and other receivables	38	24	6	10	—
Employee receivables	—	5	—	—	—
Marketable securities, current	146	62	—	—	—
Restricted cash	1	—	—	—	—
Total current assets	676	863	347	478	—
Marketable securities, net of current portion	93	—	—	—	—
Property, plant and equipment, net	383,000	242,000	46,000	34,000	—
Operating right of use asset	185,000	431,000	55,000	120,000	—
Intangible assets	407,000	534,000	170,000	208,000	—
Total assets	769	865	347	478	—
Accounts payable	9	5	17	12	—
Accrued expenses and other current liabilities	15	14	11	6	—
Deferred revenue, current	4	6	9	14	—
Lease liability, current	136,000	246,000	60,000	66,000	—
Derivative earnout liability, current	—	45	—	—	—
Derivative warrant liabilities	57	38	13	4	—
Total current liabilities	86	107	50	36	—
Lease liability, net of current portion	66,000	202,000	—	60,000	—
Total liabilities	86	107	59	48	—
Commitments and contingencies (Note 13)	—	—	—	—	—
Ordinary shares	14	13	10	10	—
Additional paid-in capital	1,427	1,298	591	556	—
Accumulated loss	−762	−559	−317	−140	—
Accumulated other comprehensive income	5	4	4	4	—
Total shareholders' equity	683	758	288	430	−114
Total liabilities and shareholders' equity	769	865	347	478	—

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Loss for the year	−204	−242	−177	−23	−42
Depreciation and amortization	220,000	113,000	49,000	9,000	5,000
Non-cash rent expense	—	12,000	6,000	10,000	2,000
Fair value change - derivative earnout and warrants	19	76	10	1	—
Loss on disposal of property, plant and equipment	12,000	—	—	—	—
Amortization of premium/discount on available-for-sale debt securities	−1	−227,000	—	—	—
Share-based compensation	59	34	25	4	1
Changes in prepayments (current and non-current) and other receivables	−13	−17	4	−4	−5
Changes in accounts payable	5	−13	5	5	7
Changes in accrued expenses and other current liabilities	2	2	5	−9	3
Changes in deferred revenue	−2	−4	−9	18	—
Net cash used in operating activities	−148	−159	−141	11	−30
Purchase of property, plant and equipment, including internal use software	−246,000	−672,000	−24,000	−221,000	−24,000
Maturities of marketable securities	122	—	—	—	—
Purchases of marketable securities	−297	−62	—	—	—
Net cash used in investing activities	−175	−63	−24,000	−221,000	−24,000
Proceeds from exercise of warrants	2	14	9	—	—
Proceeds from exercise of options	29	2	290,000	—	—
Payment of withholding taxes related to net share settlement of exercised options	—	−989,000	—	—	—
Net cash provided by financing activities	30	660	9	392	85
Net change in cash, cash equivalents and restricted cash	−293	438	−132	402	55
Foreign exchange differences	13	−7	5	5	−5
Recognition of ROU asset	—	562,000	—	—	196,000
Issuance of earnout shares	41	—	—	—	—
Cash paid for income taxes	—	1,000	27,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro